In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corporate VCs Step Up Carefully to Fill VC Void

Executive Summary

As institutional venture firms gird themselves for difficult times ahead in raising new funds, investment programs at pharmaceutical companies and large medical device companies are at least partially filling the gap by committing corporate dollars into private life sciences companies, even in earlier stages.
Advertisement

Related Content

Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year
Some VC Funds Have Miles To Go While Others Have Burned What's In The Tank
Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy
Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy
Corporate VC Backing Influences Private M&A Step-Ups

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel